Cahill Represents ICON plc in its Acquisition of MolecularMD

February 21, 2019

Cahill represented ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, in connection with its acquisition of MolecularMD, a Portland, OR-based molecular diagnostics lab.  The acquisition expands ICON’s footprint in molecular testing, including next-gen sequencing and immunohistochemistry, and extends its reach into the support of precision medicine programs.